Novo Nordisk will make an investment of 2,300 million dollars in a plant located in Chartres, France, with the objective of increasing the production of its outstanding medications for diabetes and weight loss.
The Danish pharmaceutical company seeks to meet growing demand, significantly improving the manufacturing capacity of drugs such as Ozempic and Wegovy, as well as other obesity treatments that are in the development phase.
The measure responds to the Ozempic supply crisis in Europe, a treatment for diabetes that shares the active ingredient, semaglutide, with the popular weight loss drug Wegovy, still not available in the region.
Additionally, this week, Novo Nordisk has restricted the use of Ozempic in the European Union due to its uncontemplated use, and countries such as Germany and Belgium are considering measures such as evaluating the prohibition of exports or restricting the prescription of the medication.
With information from: Forbes.
Receive all industry news in our weekly Newsletter Scientific Dialectics.